<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02701166</url>
  </required_header>
  <id_info>
    <org_study_id>NL48885.018.15</org_study_id>
    <nct_id>NCT02701166</nct_id>
  </id_info>
  <brief_title>The Effect of Bezafibrate on Cholestatic Itch</brief_title>
  <acronym>FITCH</acronym>
  <official_title>The Effect of Bezafibrate on Cholestatic Itch</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Free University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ludwig-Maximilians - University of Munich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Friedrich-Alexander-Universität Erlange-Nürnberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Clinico Humanitas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized double blind placebo controlled trial to evaluate the antipruritic effect of
      bezafibrate in patients with moderate to severe cholestatic itch.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2016</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with a reduction in itch intensity of 50% or more</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum liver tests</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinine</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum cholesterol</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum autotaxin activity</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum creatinin kinase</measure>
    <time_frame>3 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Primary Biliary Cholangitis</condition>
  <condition>Primary Sclerosing Cholangitis</condition>
  <condition>Secondary Sclerosing Cholangitis</condition>
  <arm_group>
    <arm_group_label>Bezafibrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bezalip retard 400mg tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 400mg tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bezafibrate</intervention_name>
    <description>bezafibrate 400mg per day</description>
    <arm_group_label>Bezafibrate</arm_group_label>
    <other_name>bezalip</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo 400mg per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of primary biliary cholangitis or primary/secondary sclerosing cholangitis
             as defined by EASL clinical practice guidelines of cholestasis 2009;

          -  itch without primary dermatologic abnormalities and with an intensity score of ≥ 5.0
             cm on a scale from 0.0 cm (no itch) to 10.0 cm (worst itch possible), scored twice in
             the week before inclusion.

        Exclusion Criteria:

          -  Concomitant guideline-recommended as well as experimental antipruritic therapy, e.g.

        rifampicin, opioid-receptor antagonists (naltrexon, naloxone), serotonin-reuptake
        inhibitors (sertraline), ondansetron, phenobarbital, propofol, lidocaine, dronabinol,
        butorphanol, internal or external biliary drainage, extracorporeal albumin dialysis,
        ultraviolet-B phototherapy; NB. Topical menthol containing agents are allowed, as well as
        bile salt sequestrants (colesevelam, cholestyramin) as long as taken at least 4 hours
        before or after intake of the study medication. Incidental use of these agents should be
        noted by patients in the diary, structural use should be noted on the CRF (section
        co-medication);

          -  Pregnancy, women of childbearing potential not using contraception, breast feeding;

          -  Cholestasis due to obstruction that requires invasive desobstructive treatment within
             the time scope of the study (5 weeks), such as endoscopic retrograde
             cholangiopancreaticography (ERCP) or surgical removal of a tumor compressing the bile
             duct;

          -  Use of opiates;

          -  Renal insufficiency (creatinine clearance &lt;60mL/min).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Academic Medical Center</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ulrich Beuers, prof. dr.</last_name>
      <phone>+31205662422</phone>
      <email>u.h.beuers@amc.uva.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ruth Bolier</last_name>
      <phone>+31205668701</phone>
      <email>a.r.bolier@amc.uva.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Ulrich Beuers, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsemieke de Vries</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vrije Universiteit Medisch Centrum</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin van Nieuwkerk, dr.</last_name>
      <phone>+31-20-4440613</phone>
      <email>cmj.vannieuwkerk@vumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Ineke Jansen</last_name>
      <phone>+31-20-4449455</phone>
      <email>a.jansen1@vumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marleen de Vree, dr.</last_name>
      <phone>+31-6-55256255</phone>
      <email>j.m.l.de.vree@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lyda Engelsman</last_name>
      <phone>+31-50-3614996</phone>
      <email>a.f.engelsman@umcg.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Leids Universitair Medisch Centrum</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bart van Hoek, prof. dr.</last_name>
      <phone>+31-71-5263507</phone>
      <email>b.van_hoek@lumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Lida Beneken Kolmer</last_name>
      <phone>+31-71-5261188</phone>
      <email>a.beneken_kolmer@lumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Jansen, prof. dr.</last_name>
      <phone>+31-43-3876543</phone>
      <email>plm.jansen@maastrichtuniversity.nl</email>
    </contact>
    <contact_backup>
      <last_name>Tine Horsten</last_name>
      <phone>+31-43-3874436</phone>
      <email>t.horsten@mumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Radboud Universitair Medisch Centrum</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joost Drenth, prof. dr.</last_name>
      <phone>+31-24-3613999</phone>
      <email>joostphdrenth@cs.com</email>
    </contact>
    <contact_backup>
      <last_name>Sonja Cuppen</last_name>
      <phone>+31-24-3619190</phone>
      <email>researchunit.mdl@radboudumc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henk van Buuren, dr.</last_name>
      <phone>+31-10-7035942</phone>
      <email>h.vanbuuren@erasmusmc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Maren Harms</last_name>
      <phone>+31-10-7038922</phone>
      <email>m.h.harms@erasmusmc.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karel van Erpecum, dr.</last_name>
      <phone>+31-88-7555555</phone>
      <email>k.j.vanerpecum@umcutrecht.nl</email>
    </contact>
    <contact_backup>
      <last_name>Janneke van den Brink</last_name>
      <phone>+31-88-7557973</phone>
      <email>j.vandenbrink@umcutrecht.nl</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Albert Parés, dr.</last_name>
      <phone>+34-93-2275753</phone>
      <email>pares@ub.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2016</study_first_submitted>
  <study_first_submitted_qc>March 4, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2016</study_first_posted>
  <last_update_submitted>March 4, 2016</last_update_submitted>
  <last_update_submitted_qc>March 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 8, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</investigator_affiliation>
    <investigator_full_name>Ruth Bolier</investigator_full_name>
    <investigator_title>prof. dr. Ulrich Beuers</investigator_title>
  </responsible_party>
  <keyword>Pruritus</keyword>
  <keyword>itch</keyword>
  <keyword>cholestasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
    <mesh_term>Liver Cirrhosis, Biliary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bezafibrate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

